RHYTHM PHARMACEUTICALS INC's ticker is RYTM and the CUSIP is 76243J105. A total of 127 filers reported holding RHYTHM PHARMACEUTICALS INC in Q1 2021. The put-call ratio across all filers is 2.15 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $201,167 | +36.3% | 8,775 | -1.9% | 0.00% | 0.0% |
| Q2 2023 | $147,569 | -9.2% | 8,949 | -1.7% | 0.00% | 0.0% |
| Q1 2023 | $162,487 | -18.9% | 9,108 | +32.4% | 0.00% | 0.0% |
| Q4 2022 | $200,316 | +31.8% | 6,879 | +11.2% | 0.00% | 0.0% |
| Q3 2022 | $152,000 | +850.0% | 6,188 | +65.4% | 0.00% | – |
| Q2 2022 | $16,000 | -62.8% | 3,742 | 0.0% | 0.00% | – |
| Q1 2022 | $43,000 | -20.4% | 3,742 | -30.7% | 0.00% | – |
| Q4 2021 | $54,000 | -26.0% | 5,398 | -3.1% | 0.00% | – |
| Q3 2021 | $73,000 | -33.0% | 5,571 | 0.0% | 0.00% | -100.0% |
| Q2 2021 | $109,000 | -6.8% | 5,571 | +1.3% | 0.00% | 0.0% |
| Q1 2021 | $117,000 | +5.4% | 5,502 | +47.0% | 0.00% | 0.0% |
| Q4 2020 | $111,000 | +37.0% | 3,742 | 0.0% | 0.00% | 0.0% |
| Q3 2020 | $81,000 | -2.4% | 3,742 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $83,000 | +151.5% | 3,742 | +71.2% | 0.00% | – |
| Q1 2020 | $33,000 | -34.0% | 2,186 | 0.0% | 0.00% | – |
| Q4 2019 | $50,000 | – | 2,186 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Opaleye Management Inc. | 810,000 | $19,845,000 | 8.20% |
| NEA Management Company, LLC | 4,912,306 | $108,316,000 | 5.41% |
| Frazier Life Sciences Management, L.P. | 1,894,000 | $46,403,000 | 3.57% |
| RA Capital Management | 5,471,067 | $134,041,000 | 2.86% |
| Samsara BioCapital, LLC | 345,293 | $8,460,000 | 1.97% |
| Altium Capital Management LP | 170,000 | $4,165,000 | 1.53% |
| Parkman Healthcare Partners LLC | 187,989 | $4,606,000 | 1.31% |
| Rock Springs Capital Management LP | 1,760,865 | $43,141,000 | 1.11% |
| EAM Investors, LLC | 198,699 | $4,868,000 | 1.06% |
| Prosight Management, LP | 80,000 | $1,960,000 | 1.05% |